- Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
- Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
- Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
- Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
- Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
- Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
- Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
- Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
- Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
More ▼
Key statistics
On Wednesday, Amylyx Pharmaceuticals Inc (AMLX:NSQ) closed at 1.83, 7.65% above its 52-week low of 1.70, set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.79 |
---|---|
High | 1.85 |
Low | 1.78 |
Bid | 1.83 |
Offer | 1.84 |
Previous close | 1.83 |
Average volume | 1.36m |
---|---|
Shares outstanding | 68.01m |
Free float | 58.03m |
P/E (TTM) | -- |
Market cap | 124.45m USD |
EPS (TTM) | -1.07 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼